NCT05190172 (PRO-GLIO) is a NA clinical trial of Radiation therapy in Oligodendroglioma, sponsored by Oslo University Hospital.

Who is sponsoring NCT05190172?

NCT05190172 is sponsored by Oslo University Hospital.

What drugs are being tested in NCT05190172?

Interventions in NCT05190172: Radiation therapy.

What condition does NCT05190172 study?

NCT05190172 studies Oligodendroglioma, Oligodendroglioma, Anaplastic, Diffuse Astrocytoma, IDH-Mutant.

Is NCT05190172 still recruiting?

NCT05190172 is currently recruiting now. Last updated 12 February 2025.

Last reviewed 2025-02-12 · How we verify

NCT05190172: PRO-GLIO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Recruiting now NA Last updated 12 February 2025

What this trial tests

NA trial testing Radiation therapy in Oligodendroglioma in 225 participants. Currently enrolling.

Timeline

14 January 2022

Primary endpoint
31 December 2027

31 December 2043

Quick facts

Lead sponsor	Oslo University Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	225
Start date	14 January 2022
Primary completion	31 December 2027
Estimated completion	31 December 2043
Sites	1 location across Norway

Drugs / interventions tested

Radiation therapy — full drug profile →

Conditions studied

Oligodendroglioma — all drugs for Oligodendroglioma →
Oligodendroglioma, Anaplastic — all drugs for Oligodendroglioma, Anaplastic →
Diffuse Astrocytoma, IDH-Mutant — all drugs for Diffuse Astrocytoma, IDH-Mutant →

Sponsor

Oslo University Hospital

Who can join

Adults 18 to 65, any sex, with Oligodendroglioma or Oligodendroglioma, Anaplastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proton therapy is a powerful tool enabling oncologists to spare normal tissue around the target for irradiation much better than what can be achieved with photon irradiation. The infiltrative nature of IDH-mutated grade II and III diffuse glioma, however, renders proton therapy a potential problem. A randomized controlled trial (RCT) is the only option when trying to ensure that chances of long-term survival are not impaired seeking to reduce unwanted late treatment effects. Non-inferiority of proton therapy compared to photon irradiation is the primary endpoint of the RCT. Hence, PRO-GLIO has two main objectives. First, PRO-GLIO will evaluate if proton therapy is safe in patients with IDH-mutated grade II and III diffuse glioma, showing that survival figures at 2 years from radiotherapy are not poorer in the proton arm than in the photon arm. Second, we want to find the true number of patients in need of rehabilitation in both arms, and evaluate if proton therapy conveys a higher QoL than photon irradiation at 2 years from radiotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

How proton therapy fits into the management of adult intracranial tumors.
Kotecha R, La Rosa A, Mehta MP. · · 2024 · cited 9× · PMID 38437667 · DOI 10.1093/neuonc/noad183
Investigating survival, quality of life and cognition in PROton versus photon therapy for <i>IDH-</i>mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden.
Heggebø LC, Borgen IMH, Rylander H, Kiserud C, et al · · 2023 · cited 8× · PMID 36940951 · DOI 10.1136/bmjopen-2022-070071
Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.
Eekers DBP, Zegers CML, Ahmed KA, Amelio D, et al · · 2024 · cited 7× · PMID 39006517 · DOI 10.1093/nop/npae040
Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.
Svenjeby C, Carstam L, Werlenius K, Bontell TO, et al · · 2022 · cited 5× · PMID 36434487 · DOI 10.1007/s11060-022-04136-y
Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.
Pinkham MB, Sim HW, Jeffree RL, Lasocki A, et al · · 2026 · PMID 41881841 · DOI 10.1111/ajco.70070
Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE).
Dasgupta A, Ghosh S, Chatterjee A, Kannan S, et al · · 2026 · PMID 41689093 · DOI 10.1186/s13014-025-02785-7
Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study.
Goliot N, Jouglar E, Jacob J, Christy F, et al · · 2025 · PMID 40764578 · DOI 10.1186/s13014-025-02702-y
Protons or Photons in Pituitary Neuroendocrine Tumors-That Is Not the Question.
Heggebø LC, Garrote FLB, Fjæra LF, Hervani M, et al · · 2025 · PMID 40678408 · DOI 10.1016/j.ijpt.2025.101194

Verify or expand the search:

Other trials of Radiation therapy

Trials testing the same drug.

NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06831526 — Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05608369 — Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC · Phase 2 · withdrawn
NCT06702033 — The Minimalist Trial-2 · Phase 2 · recruiting
NCT06583070 — SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer · recruiting

Other recruiting trials for Oligodendroglioma

Currently open trials in the same condition.

NCT06989086 — FearLess in NeuroOncology · NA · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT05303519 — SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) · Phase 3 · recruiting
NCT05561374 — Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma · Phase 1 · active not recruiting
NCT05484622 — Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma · Phase 1 · active not recruiting

Other Oslo University Hospital trials

Trials by the same sponsor.

NCT07463885 — Spontaneous vs Controlled Mechanical Ventilation in Acute Hypoxemic Respiratory Failure · NA · not yet recruiting
NCT07427719 — Retinopathy of Prematurity - Visual Function and Retinal Structure · not yet recruiting
NCT07403331 — Severe Chronic Neuropathic Pain: A Treatment Bundle, Using Spinal Cord Stimulation and Multidisciplinary Treatment, to R · NA · recruiting
NCT07449897 — Cholecystectomy With Intraoperative Management of Bile Duct Stones in Norway - the BILNOR Study · recruiting
NCT06173817 — The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05190172 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University Hospital
Last refreshed: 12 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05190172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing